Abstract
Introduction
Endoscopic treatment with the duodenal-jejunal bypass liner (DJBL) leads to significant weight loss in obese patients. We sought to identify clinical factors associated with weight loss in obese patients treated with the DJBL for 1 year.
Methods
Subjects with morbid obesity were enrolled in a single-arm, open-label, prospective trial and implanted with the DJBL. Patient demographics along with baseline comorbidities, anthropometrics, and biochemical variables were selected for univariate and multivariate analysis.
Results
The DJBL was implanted in 79 subjects and 61 completed 12 months of follow-up. There were 18 early removals. Baseline mean age and body mass index (BMI) were 35.4 ± 9.7 years and 43 ± 5.6 kg/m2, respectively. Forty-four (72 %) were women. This population included 22 subjects with type 2 diabetes (T2DM). Twelve months after treatment, patients had a mean excess body weight loss (%EBWL) of 46 ± 18 %. Univariate analysis identified that fasting glycemia (r 2 = −0.303, p < 0.013), insulin-resistance determined by HOMA-IR (r 2 = −0.457, p < 0.019), and glycated hemoglobin (HbA1c) (r 2 = −0.471, p < 0.013) were associated inversely with %EBWL at 1 year. In this cohort of patients, the multivariate analysis indicated that only baseline HbA1c levels were associated inversely with %EBWL after 1 year of treatment (β adjusted coefficient −0.758, p < 0.016). Importantly, no differences at 1 year in %EBWL were observed between patients with or without T2DM (%EBWL T2D 46.7 ± 20 % vs. non-T2DM 46.8 ± 18.6 %, p = 0.988).
Conclusions
This analysis indicates that higher baseline HbA1c levels are associated independently with diminished body weight loss in obese patients treated with the DJBL independent of their diabetic status. These results show that DJBL induces clinically significant weight loss in both T2DM and non-T2DM patients.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
(1993) Methods for voluntary weight loss and control. NIH Technology Assessment Conference Panel. Consensus development conference, 30 March to 1 April 1992. Ann Intern Med 119:764–770
Wadden TA, Brownell KD, Foster GD (2002) Obesity: responding to the global epidemic. J Consult Clin Psychol 70:510–525
Escalona A, Pimentel F, Sharp A, Becerra P, Slako M, Turiel D, Munoz R, Bambs C, Guzman S, Ibanez L, Gersin K (2012) Weight loss and metabolic improvement in morbidly obese subjects implanted for 1 year with an endoscopic duodenal-jejunal bypass liner. Ann Surg 255:1080–1085
de Moura EG, Orso IR, Martins Bda C, Lopes GS, de Oliveira SL, Galvao-Neto Mdos P, Mancini MC, Santo MA, Sakai P, Ramos AC, Garrido-Junior AB, Halpern A, Cecconello I (2011) Improvement of insulin resistance and reduction of cardiovascular risk among obese patients with type 2 diabetes with the duodenojejunal bypass liner. Obes Surg 21:941–947
Hatoum IJ, Stein HK, Merrifield BF, Kaplan LM (2009) Capacity for physical activity predicts weight loss after Roux-en-Y gastric bypass. Obesity (Silver Spring) 17:92–99
Yip K, Heinberg L, Giegerich V, Schauer PR, Kashyap SR (2012) Equivalent weight loss with marked metabolic benefit observed in a matched cohort with and without type 2 diabetes 12 months following gastric bypass surgery. Obes Surg 22:1723–1729
Livhits M, Mercado C, Yermilov I, Parikh JA, Dutson E, Mehran A, Ko CY, Gibbons MM (2012) Preoperative predictors of weight loss following bariatric surgery: systematic review. Obes Surg 22:70–89
Chen EY, McCloskey MS, Doyle P, Roehrig J, Berona J, Alverdy J, le Grange D (2009) Body mass index as a predictor of 1-year outcome in gastric bypass surgery. Obes Surg 19:1240–1242
Melton GB, Steele KE, Schweitzer MA, Lidor AO, Magnuson TH (2008) Suboptimal weight loss after gastric bypass surgery: correlation of demographics, comorbidities, and insurance status with outcomes. J Gastrointest Surg 12:250–255
Campos GM, Rabl C, Mulligan K, Posselt A, Rogers SJ, Westphalen AC, Lin F, Vittinghoff E (2008) Factors associated with weight loss after gastric bypass. Arch Surg 143:877–883 discussion 884
Ma Y, Pagoto SL, Olendzki BC, Hafner AR, Perugini RA, Mason R, Kelly JJ (2006) Predictors of weight status following laparoscopic gastric bypass. Obes Surg 16:1227–1231
Alvarado R, Alami RS, Hsu G, Safadi BY, Sanchez BR, Morton JM, Curet MJ (2005) The impact of preoperative weight loss in patients undergoing laparoscopic Roux-en-Y gastric bypass. Obes Surg 15:1282–1286
Perugini RA, Mason R, Czerniach DR, Novitsky YW, Baker S, Litwin DE, Kelly JJ (2003) Predictors of complication and suboptimal weight loss after laparoscopic Roux-en-Y gastric bypass: a series of 188 patients. Arch Surg 138:541–545 discussion 545–546
Lutfi R, Torquati A, Sekhar N, Richards WO (2006) Predictors of success after laparoscopic gastric bypass: a multivariate analysis of socioeconomic factors. Surg Endosc 20:864–867
Hatoum IJ, Stein HK, Merrifield BF, Kaplan LM (2008) Capacity for physical activity predicts weight loss after Roux-en-Y gastric bypass. Obesity (Silver Spring) 17:92–99
Gersin KS, Rothstein RI, Rosenthal RJ, Stefanidis D, Deal SE, Kuwada TS, Laycock W, Adrales G, Vassiliou M, Szomstein S, Heller S, Joyce AM, Heiss F, Nepomnayshy D (2010) Open-label, sham-controlled trial of an endoscopic duodenojejunal bypass liner for preoperative weight loss in bariatric surgery candidates. Gastrointest Endosc 71:976–982
Schouten R, Rijs CS, Bouvy ND, Hameeteman W, Koek GH, Janssen IM, Greve JW (2010) A multicenter, randomized efficacy study of the EndoBarrier Gastrointestinal Liner for presurgical weight loss prior to bariatric surgery. Ann Surg 251:236–243
Tarnoff M, Rodriguez L, Escalona A, Ramos A, Neto M, Alamo M, Reyes E, Pimentel F, Ibanez L (2009) Open label, prospective, randomized controlled trial of an endoscopic duodenal-jejunal bypass sleeve versus low calorie diet for pre-operative weight loss in bariatric surgery. Surg Endosc 23:650–656
Cohen RV, Neto MG, Correa JL, Sakai P, Martins B, Schiavon CA, Petry T, Salles JE, Mamedio C, Sorli C (2013) A pilot study of the duodenal-jejunal bypass liner in low body mass index type 2 diabetes. J Clin Endocrinol Metab 98:E279–E282
de Moura EG, Martins BC, Lopes GS, Orso IR, de Oliveira SL, Galvao Neto MP, Santo MA, Sakai P, Ramos AC, Garrido Junior AB, Mancini MC, Halpern A, Cecconello I (2012) Metabolic improvements in obese type 2 diabetes subjects implanted for 1 year with an endoscopically deployed duodenal-jejunal bypass liner. Diabetes Technol Ther 14:183–189
Papalazarou A, Yannakoulia M, Kavouras SA, Komesidou V, Dimitriadis G, Papakonstantinou A, Sidossis LS (2010) Lifestyle intervention favorably affects weight loss and maintenance following obesity surgery. Obesity (Silver Spring) 18:1348–1353
Acknowledgments
GI Dynamics (Lexington, MA) provided funding for this research project.
Disclosures
Dr. Alex Escalona received a consulting fee from GI Dynamics, Inc., and served as a research grant study investigator for GI Dynamics, Inc. Rodrigo Munoz, Angelica Dominguez, Fernando Munoz, Cesar Munoz, Milenko Slako, Dannae Turiel, Fernando Pimentel, and Alan Sharp have no conflicts of interest or financial ties to disclose.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Muñoz, R., Dominguez, A., Muñoz, F. et al. Baseline glycated hemoglobin levels are associated with duodenal-jejunal bypass liner-induced weight loss in obese patients. Surg Endosc 28, 1056–1062 (2014). https://doi.org/10.1007/s00464-013-3283-y
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00464-013-3283-y